Abaloparatide Fracture Reductions Sustained in Osteoporosis Abaloparatide Fracture Reductions Sustained in Osteoporosis

Final results from the ACTIVExtend trial show sustained reductions with the osteoanabolic drug for 2 years after switching to a bisphosphonate, an effect that one expert commented is"impressive."Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news